AngioDynamics (ANGO) Reports In-Line Q1 EPS, Offers Q2 and FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Canaccord Genuity Cuts Price Target on AngioDynamics (ANGO) Following 1Q16
October 9, 2015 8:55 AM EDTCanaccord Genuity maintained a Buy rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $17.50 (from $19.00), following the company's 1Q16 earnings results. ANGOs salesforce has now converted approximately 45% of Morpheus customers over to BioFlow, with BioFlow PICC sales up 22% during the quarter.... More
Piper Jaffray Cuts Price target on AngioDynamics (ANGO) Following 1Q16 Results
October 9, 2015 8:12 AM EDTPiper Jaffray maintained a Neutral rating on AngioDynamics (NASDAQ: ANGO), and cut the price target to $14.00 (from $18.00), following the company's 1Q16 earnings results. Revenues missed, coming in at $83.7M, and earnings were in line with expectations.
Analyst Thomas Gunderson commented, "ANGO essentially... More
